Benzinga | Apr 29, 2021 07:31AM EDT

Cara Therapeutics Announces Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus Did Not Meet Primary Endpoint

-- Study did not meet Primary Endpoint of worst-itch NRS change from baseline at

week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population

-- Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients (64% of ITT patient population) --

-- Statistically significant improvement in 4-point responder analysis in

mild-to-moderate (BSA <10%) AD patients with 32% of KORSUVA-treated patients achieving a > 4-point reduction vs. 19% in placebo group (p=0.03) --

-- KORSUVA was well tolerated at all dose levels --

-- Company to host conference call today at 8:00 a.m. ET --